MedPath
FDA Approval

ZONTIVITY

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
April 8, 2021
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Vorapaxar(2.08 mg in 1 1)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

ZONTIVITY

Product Details

NDC Product Code
70347-208
Application Number
NDA204886
Marketing Category
NDA (C73594)
Route of Administration
ORAL
Effective Date
April 8, 2021
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5XClass: IACT
CELLULOSE, MICROCRYSTALLINEInactive
Code: OP1R32D61UClass: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30Class: IACT
CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48Class: IACT
VorapaxarActive
Code: IN66038E6CClass: ACTIMQuantity: 2.08 mg in 1 1
HYPROMELLOSE 2910 (15 MPA.S)Inactive
Code: 36SFW2JZ0WClass: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JPClass: IACT
TRIACETINInactive
Code: XHX3C3X673Class: IACT
FERRIC OXIDE YELLOWInactive
Code: EX438O2MRTClass: IACT
POVIDONEInactive
Code: FZ989GH94EClass: IACT
© Copyright 2025. All Rights Reserved by MedPath